fda sued over tirzepatide US judge denies injunction, restricting copies of Lilly weight-loss drug

Mounjaro will remain off shortage list after FDA review

20.83

★★★★☆4.8 (126)

The FDA's recent decision to remove tirzepatide from its shortage list has triggered a legal battle with significant implications for medical spas and compounders. In response to a lawsuit filed by the

20.33

★★★★★4.9 (98)

Minus one of its GLP-1 cash cows, compounding group sues FDA

23.55

★★★★★5.0 (157)

Drug compounders sue US FDA over removal of Wegovy, Ozempic from shortage list

23.09

★★★★★4.7 (84)

The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight-loss results, Retatrutide

24.83

★★★★★4.9 (203)

🚨 FDA Moves to Permanently Shut Down Compounded GLP-1s The FDA is taking steps to eliminate large-scale compounding of GLP-1 medications like semaglutide and tirzepatide, signaling a major shift in how these

26.09

★★★★★5.0 (176)

GLP-1 Drugs: FDA Sued Over Removing Tirzepatide from the Drug Shortage List

23.08

★★★★★4.8 (132)